Aeolus Pharmaceuticals, Inc. is involved in the development of a new class of broad-spectrum, catalytic-antioxidant compounds which will protect healthy tissue from the damaging effects of radiation. The company’s first compound, AEOL 10150, is being developed as a medical countermeasure against radiological and chemical weapons. The compound’s initial target indications are as a protective agent against the effects of acute radiation syndrome and the delayed effects of acute radiation exposure. For more information, visit the company’s website at www.aolsrx.com.